Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
40°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
957.00
+19.39 (+2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...
Via
Benzinga
Exposures
Product Safety
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
March 22, 2024
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.
Via
InvestorPlace
Regeneron Pharmaceuticals Unusual Options Activity For March 20
March 20, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
March 15, 2024
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
March 13, 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.
Via
InvestorPlace
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
March 01, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via
Benzinga
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
March 08, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
These stocks are worth buying in most months of the year.
Via
The Motley Fool
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
February 22, 2024
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
February 21, 2024
These stocks are used to beating the market.
Via
The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
February 06, 2024
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
February 26, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
February 20, 2024
The FDA put studies in eczema and asthma treatment on clinical hold.
Via
Investor's Business Daily
Exposures
Product Safety
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
February 20, 2024
The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
2 Top Growth Stocks to Buy With $1,000 Right Now
February 18, 2024
Even a modest starting investment in the right stocks could pay off in the years ahead.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
February 09, 2024
There's room for multiple winners in the fast-growing weight-loss market.
Via
The Motley Fool
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
February 06, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.
Via
Benzinga
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
February 06, 2024
Via
Benzinga
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
February 06, 2024
Investors might continue bidding up shares of these companies regardless.
Via
The Motley Fool
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
February 05, 2024
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.
Via
Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.